Skip to main content

Table 2 Base-case results (health and economic outcomes)

From: Vancomycin-resistant enterococci (VRE) screening and isolation in the general medicine ward: a cost-effectiveness analysis

Outcomes VRE screening and isolation No VRE screening and isolation Differencea (%)
Non-isolated cases 11/1000 60/1000 −49/1000 (82%)
Healthcare-associated VRE-colonisation 2/1000 8/1000 −6/1000 (73%)
Infected cases 5.7/1000 6.3/1000 −0.6/1000 (10%)
VRE-related bacteremia 2.6/1000 2.8/1000 −0.2/1000 (7%)
Other VRE infections (e.g. UTI) 3.2/1000 3.6/1000 −0.4/1000 (12%)
Deaths subsequent to VRE infection 0.5/1000 0.6/1000 −0.1/1000 (8%)
ICER ($/QALY)    7850
 Total costs ($) 118.37 6.72 112
 Total QALY gained 20.5607 20.5465 0.0142
  1. aDifference for health outcomes were calculated by subtracting “no VRE screening and isolation strategy” outcomes from “VRE screening and isolation strategy” outcomes. Percentage change was calculated relative to “no VRE screening and isolation strategy” outcomes
  2. ICER incremental cost-effectiveness ration, QALY quality-adjusted life years, UTI urinary tract infection, VRE vancomycin-resistant enterococci